S4194

SR 12813

≥98%, solid

• Synonim(y): Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate
• Wzór empiryczny (zapis Hilla): C₂₄H₄₂O₇P₂
• Numer CAS: 126411-39-0
• Masa cząsteczkowa: 504.53
• NACRES: NA.77
• PubChem Substance ID: 329824541
• UNSPSC Code: 12352203
• MDL number: MFCD00888473
• Assay: ≥98%
• Form: solid

Właściwości

• biological source: synthetic (organic)
• Quality Segment: 100
• assay: ≥98%
• form: solid
• solubility: DMSO: ≥10 mg/mL, H₂O: insoluble
• originator: GlaxoSmithKline
• SMILES string: CCOP(=O)(OCC)C(=C/c1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)\P(=O)(OCC)OCC
• InChI: 1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3
• InChI key: YQLJDECYQDRSBI-UHFFFAOYSA-N

Opis

Application

SR-12813 was used as control in pregnane X receptor (PXR) binding assay performed in HepG2 liver carcinoma cells and PXR-activation assay mediated by dehydroepiandrosterone in human hepatocytes.

Biochem/physiol Actions

SR 12813 is a pregnane X receptor (PXR, NR 112) agonist; cholesterol lowering drug; HMGCoA reductase inhibitor.

SR-12813 is a 1,1-bisphosphonate ester that exhibits hypocholesterolemic activity. It decreases the biosynthesis of cholesterol by enhancing the degradation of HMG-CoA reductase.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)